Development of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library
Authors:
- Gihan S. GunaratneGGGihan S. Gunaratne
- Joseph P. GallantJGJoseph P. Gallant
- Kendahl L. OttKOKendahl L. Ott
- Jayden L. WestJWJayden L. West
- Jason C. MixdorfJMJason C. Mixdorf
- Eduardo Aluicio-SarduyEAEduardo Aluicio-Sarduy
- Jonathan W. EngleJonathan W. Engle
- Eszter BorosEBEszter Boros
- Labros MeimetisLMLabros Meimetis
- Joshua M. LangJLJoshua M. Lang
Preprint
Abstract
Cancer-associated fibroblasts (CAFs) in the stroma of solid tumors promote an immunosuppressive tumor microenvironment (TME) that drives resistance to therapies. The expression of the protease fibroblast activation protein (FAP) on the surface of CAFs has made FAP a target for development of therapies to dampen immunosuppression. Relatively few biologics have been developed for FAP and none have been developed that exploit the unique engagement properties of Variable New Antigen Receptors (VNARs) from shark antibodies. As the smallest binding domain in nature, VNARs cleverage unique geometries and recognize epitopes conventional antibodies cannot. By directly immunizing a nurse shark with FAP, we created a large anti-FAP VNAR phage display library. This library allowed us to identify a suite of anti-FAP VNARs through traditional biopanning and also by an in silico approach that did not require any prior affinity-based enrichment in vitro . We investigated four VNAR-Fc fusion proteins for theranostic properties and found that all four recognized FAP with high affinity and were rapidly internalized by FAP-positive cells. As a result, the VNAR-Fc constructs were effective antibody-drug conjugates in vitro and were able to localize to FAP-positive xenografts in vivo . Our findings establish VNAR-Fc constructs as a versatile platform for theranostic development that could yield innovative cancer therapies targeting the TME.Keywords
This publication has 61 references indexed in Scilit:
- Identification and biophysical characterization of a novel domain-swapped camelid antibody specific for fentanylJournal of Biological Chemistry, 2024
- Fibroblasts in cancer: Unity in heterogeneityCell, 2023
- Fibroblast Activation Protein Inhibitor TheranosticsPET Clinics, 2023
- The evolving tumor microenvironment: From cancer initiation to metastatic outgrowthCancer Cell, 2023
- Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapyDrug Delivery and Translational Research, 2023
- Role of tumor microenvironment in cancer progression and therapeutic strategyCancer Medicine, 2023
- SO-4 phase Ib/II, open-label, randomised evaluation of atezolizumab plus RO6874281 vs control in MORPHEUS–pancreatic ductal adenocarcinomaAnnals of Oncology, 2020
- Role of the immunosuppressive microenvironment in immunotherapyAdvances in Radiation Oncology, 2018
- Fibroblast activation protein (FAP) as a novel metabolic targetMolecular Metabolism, 2016
- High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosisTumor Biology, 2013